A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »
A note to our families from CEO Mark Stone
Muscle regeneration research
A complementary approach for FSHD therapeutics by Justin Cohen, New Haven, Connecticut This is an exciting time for facioscapulohumeral muscular dystrophy (FSHD) patients, with many therapeutics entering clinical trials. Most… Read More »
FSHD is not for cowards
There was plenty of ingenuity and grit on display in Denver by June Kinoshita, FSHD Society Many scientists who work on FSHD spend their days bent over test tubes and… Read More »
Meet del-brax, Avidity’s FSHD therapeutic candidate
Results presented by Avidity of interim data from its Phase 1/2 clinical trial in FSHD were all the buzz at this year’s International Research Congress and FSHD Connect conference…. Read More »
Avidity shares interim data from its FORTITUDE trial
“Unprecedented” and “consistent” reductions in DUX4 activity along with improvements in strength and function by June Kinoshita, FSHD Society Avidity Biosciences, Inc., a San Diego-based biopharmaceutical company, announced this Wednesday,… Read More »